Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Latest filing published 31 Jan 2023 for Rubius Therapeutics, Inc..
Insider track record
Disclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Laurence A. Turka: trading record in brief
Laurence A. Turka, listed as senior executive, appears in our data through filings on Rubius Therapeutics, Inc. shares, published by SEC (Form 4). We count 5 filings; the first trade dates from 29 January 2022 and the latest from 31 January 2023.
The open-market record consists of 2 sales worth €15k, with no purchase. Other entries cover 3 option exercises. So far in 2023, the count stands at no purchases and 1 sale.
The record was last updated on 31 January 2023 with an open-market sale (€574) in Rubius Therapeutics, Inc. Publication is fast: at least half of the trades appear on SEC (Form 4) on the same day. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Laurence A. Turka
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
7,438 sharesCommon StockSEC:0001104659-23-008873:0
7,438 sharesCommon StockSEC:0001179110-22-000693:0
2 of 2 declarations
